timothy sykes logo
TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum Thumbnail
G Google News

TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum

TIM SYKES•UPDATED JUL. 19, 2026, 11:07 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Trevi Therapeutics Inc. stocks have been trading up by 11.6 percent after upbeat clinical progress fueled strong investor optimism.

What Traders Need To Know

  • Shares jumped 10.9% to $19.25 in midday trade on 2026/07/17, flagging strong upside momentum.
  • Earlier that same session, price was already up 10.4% to $19.16, showing sustained buying rather than a quick spike.
  • Management is holding a non-deal roadshow with institutional investors in London on 2026/07/14, hosted by Cantor Fitzgerald.
  • Recent daily action shows a strong push from the mid-$17s into the high-$19s on heavy intraday volatility.

Candlestick Chart

Weekly Update Jul 13 – Jul 17, 2026: On Sunday, July 19, 2026 Trevi Therapeutics Inc. stock [NASDAQ: TRVI] is trending up by 11.6%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Trevi Therapeutics (TRVI) is a late-stage, single-asset specialty biotech with no revenues and deeply negative profitability metrics (ROE roughly -34% LTM, ROA -32%), typical for a development-stage platform. Balance sheet strength is a clear positive: current ratio ~25x, working capital ~$169M, cash and short-term investments ~$172M versus minimal debt ($0.7M total), implying multi-year runway despite Q1 2026 operating cash burn of ~$16.7M and free cash outflow of ~$16.8M. Valuation (P/B ~10x) embeds high expectations for nalbuphine ER.

Technically, TRVI is in a strong short-term uptrend, with the weekly sequence showing successive closes from $16.58 to $19.37 and multiple wide-range green sessions, confirming aggressive buying. Intraday 5-minute candles (noted by tight consolidations followed by breakouts) suggest momentum accumulation rather than a blow-off. An actionable level is $18.00–18.20, the nearest breakout-turned-support; as long as price holds above this zone on closing and volume remains elevated, risk-reward favors trend-following long positions with tight stops just below $18.

Recent double-digit percentage gains on July 17 occurred without new clinical data, likely reflecting positioning ahead of incremental investor engagement, including the Cantor-hosted London NDR. Versus broader Healthcare and Biotech indices, TRVI is materially outperforming YTD on sentiment and capital access, but remains a high-concentration, binary clinical story. Base case: Positive bias with near-term support at $18 and resistance around $22; constructive 6–12 month upside target range $24–26, contingent on continued clean execution.

More Breaking News

Quick Financial Overview

Trevi Therapeutics Inc. (TRVI) has just printed a powerful upside extension, with shares pushing from the mid-$17s to above $19 in one session. The weekly tape shows a steady climb: an open near $16.50 early in the week, pushing into the high $17s, briefly dipping to $17.36, then breaking to $19.37 by week’s end. That pattern tells traders this is not a one-candle anomaly, but a multi-day momentum leg. The intraday move from roughly $17.60 up to over $20 before closing near $19.07 highlights clear range expansion and aggressive bidding.

On the fundamentals, TRVI is still a classic high-risk development-stage biotech profile. The latest quarter shows revenue not highlighted and a net loss of about $13.2M, with EPS at -$0.09 and EBITDA around -$13.1M. Operating cash flow was negative at roughly -$16.7M for the quarter, and free cash flow sat near -$16.8M, so the business is still burning cash to fund operations and research. Key return metrics are deeply negative, including return on assets and return on equity, which confirms that profitability is not the current story.

Where Trevi Therapeutics Inc. stands out is its balance sheet and liquidity. Cash and cash equivalents of about $19.4M, plus a total cash and short-term investments position near $171.8M, sit against only about $7.5M of total liabilities and minimal long-term debt around $0.4M. Current and quick ratios both above 24 signal very strong short-term liquidity, giving TRVI room to fund losses for a while. With book value per share at $1.34 and a price-to-book near 10.3, traders are clearly paying up for future potential rather than present earnings, which makes sentiment and news flow — like this London roadshow — critical drivers of the chart.

Conclusion

Trevi Therapeutics Inc. is showing the kind of pattern that always grabs short-term traders’ attention: strong multi-day trend, big intraday range, and a clear news hook in the form of a sharp percentage move. The 10%+ surge to the $19–$20 area, built on top of an earlier push from the mid-$16s, tells you buyers currently control the tape. The confirmed range expansion on the intraday chart means volatility is elevated, which can be a positive for active traders but also raises risk if the move reverses.

At the same time, the financials remind us that TRVI is a cash-burning biotech with negative earnings and high valuation multiples relative to book value. The strong cash and short-term investments position, plus low debt, offers a cushion, but the company still relies on future clinical and strategic progress to justify this price. The scheduled non-deal roadshow with institutional traders suggests management is leaning into this renewed interest and trying to deepen its shareholder base. For traders, the key is to watch how price behaves around the recent highs and whether volume stays elevated on follow-through days. As I often tell my students, “Your edge comes from reading what the crowd is actually doing in the price and volume — not from guessing what the company might be worth five years from now.” As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” In this context, that means staying flexible with TRVI’s evolving price action rather than trying to force a preconceived trading thesis onto the chart.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”